Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue …

Phase III Trial Results of Eisai's Anticancer Agent Halaven(R) in Soft Tissue …

TOKYO, Feb 12, 2016 – (JCN Newswire) – Eisai Co., Ltd. announced today that the results of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven(R) (eribulin mesylate) in patients with locally advanced

(Visited 1 times, 1 visits today)
11
Like
Save

Comments

Comments are disabled for this post.